Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma

Farzaneh Ashrafi; Azadeh Moghaddas; Ali Darakhshandeh

Volume 9, Issue 1 , January 2020, , Pages 56-59

Abstract
   A combination of bortezomib, cyclophosphamide, and dexamethasone is highly effective in the treatment of newly diagnosed multiple myeloma. Neuropathy is a dose-limiting adverse ...  Read More
Management of febrile neutropenia: A description of clinical and microbiological findings by focusing on risk factors and pitfalls
Management of febrile neutropenia: A description of clinical and microbiological findings by focusing on risk factors and pitfalls

Fatemeh Karimi; Farzaneh Ashrafi; Azadeh Moghaddas; Ali Derakhshandeh

Volume 7, Issue 3 , July 2018, , Pages 147-156

Abstract
   Febrile neutropenia (FN) is one of the most serious clinical problems in patients with hematologic malignancies and patients receiving chemotherapy. The present study was implemented ...  Read More
New indications for dabigatran: A suggestion from a drug use evaluation study
New indications for dabigatran: A suggestion from a drug use evaluation study

Farzaneh Ashrafi; Najmeh Rezaie; Sarah Mousavi

Volume 6, Issue 4 , October 2017, , Pages 211-216

Abstract
   Dabigatran etexilate is a novel oral anticoagulant with several advantages over warfarin such as no need for routine monitoring and fewer drug interactions. This drug was added ...  Read More
Osteonecrosis of the jaws in patient received bisphosphonates and sunitinib separately: A case report
Osteonecrosis of the jaws in patient received bisphosphonates and sunitinib separately: A case report

Farzaneh Ashrafi; Ali Derakhshandeh; Bijan Movahedian; Azadeh Moghaddas

Volume 6, Issue 3 , July 2017, , Pages 182-185

Abstract
  Recently published reports have suggested that antiangiogenic drugs such as sunitinib could potentiate the osteonecrosis of the jaw (ONJ) induced by bisphosphonates (BPs) and even induce ...  Read More